Literature DB >> 17407218

Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation.

Kevin G Moder1, Mark H Wener, Michael H Weisman, Mariko L Ishimori, Daniel J Wallace, David L Buckeridge, Henry A Homburger.   

Abstract

OBJECTIVE: We conducted a prospective, multicenter evaluation of autoantibody testing by multiplex immunoassay in patients with known or suspected connective tissue diseases (CTD). We evaluated agreement between multiplex immunoassay and enzyme immunoassay (EIA) and assessed the diagnostic utility of autoantibody profiles.
METHODS: Samples from 908 patients with suspected CTD seen in rheumatology clinics were collected prospectively at 3 tertiary care centers. Diagnoses were established according to recognized classification criteria. Tests for autoantibodies were obtained by multiplex immunoassay and by EIA. The results of the multiplex immunoassay were analyzed using a previously validated interpretative algorithm, MDSS (Medical Decision Support Software), that suggests possible disease associations based on the pattern of results for the autoantibodies.
RESULTS: The median patient age was 49.7 years; 83% were female. The most common diagnoses were rheumatoid arthritis in 352 patients and systemic lupus erythematosus (SLE) in 332 patients. Agreement between multiplex and EIA testing ranged from a high of 99% (95% CI 98% to 100%) for Jo-1 to a low of 79% (95% CI 76% to 82%) for antinuclear antibodies. The MDSS algorithm suggested an appropriate disease association in 75% to 100% of patients with SLE. The results varied depending on the disease and the autoantibodies present.
CONCLUSION: These results suggest that patterns of autoantibodies detected by multiplex immunoassay testing, when analyzed by an interpretative algorithm, are useful in the evaluation of patients with CTD in situations of high disease prevalence. Further testing is necessary to determine its utility in settings of low disease prevalence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17407218

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests.

Authors:  Maria Infantino; M Manfredi; M Merone; V Grossi; M Benucci; F Li Gobbi; F Bandinelli; A Damiani; P Soda
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

Review 2.  Antinuclear antibody testing - misunderstood or misbegotten?

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2017-05-25       Impact factor: 20.543

3.  60 kD Ro and nRNP A frequently initiate human lupus autoimmunity.

Authors:  Latisha D Heinlen; Micah T McClain; Lauren L Ritterhouse; Benjamin F Bruner; Colin C Edgerton; Michael P Keith; Judith A James; John B Harley
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

4.  Multiple Autoantibodies Display Association with Lymphopenia, Proteinuria, and Cellular Casts in a Large, Ethnically Diverse SLE Patient Cohort.

Authors:  Rufei Lu; Julie M Robertson; Benjamin F Bruner; Joel M Guthridge; Barbara R Neas; Swapan K Nath; Jennifer A Kelly; Kathy L Moser Sivils; Eliza F Chakravarty; Diane L Kamen; Gary S Gilkeson; Daniel J Wallace; Michael H Weisman; R Hal Scofield; John B Harley; Judith A James
Journal:  Autoimmune Dis       Date:  2012-09-04

5.  The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA.

Authors:  Nancy A Stearns; Shuxia Zhou; Michelle Petri; Steven R Binder; David S Pisetsky
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.